- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01611363
A Phase 1 Study to Investigate the Mechanism of Action of Ipragliflozin
An Exploratory Study to Investigate the Effects of Ipragliflozin (ASP1941) on Glucose Homeostasis and Urinary Glucose Excretion in Healthy Subjects and Subjects With Type 2 Diabetes Mellitus (T2DM)
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
This study will consist of 2 parts. In Part A the effect of ipragliflozin on the glucose homeostasis will be investigated and in Part B we will investigate the effect of exposure of ipragliflozin on UGE and plasma glucose levels.
Part A
This part will be a randomized, double-blind, placebo-controlled, 2-
period, 2 treatment crossover design in healthy subjects and in T2DM
subjects who are drug naïve or washed out for metformin prior to
admission to the clinical site.
Part B
This part will be an open-label, randomized, 2-period, 2 treatment
crossover design in T2DM subjects stratified by baseline HbA1c
levels (6.0-6.9%, 7.0-7.9%, 8.0-8.9% or 9.0-9.9%).
Study Type
Enrollment (Actual)
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
-
Neuss, Germany, 41460
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
Inclusion Part A: Healthy subjects
- Subject is healthy without diabetes mellitus
- Subject has a fasted plasma glucose (FPG) of less than 5.6 mmol/l at screening
- Subject has a Body Mass Index (BMI) more than or equal to 18.5 and less than 28.0 kg/m2
- Subject's serum creatinine is within the normal range
Inclusion Part A: T2DM subjects
- Subject has been diagnosed with T2DM for at least 6 months
- Subject's body mass index (BMI) is equal to or more than 20.0 and less than 35.0 kg/m2 at screening
- Subject has a HbA1c level above 7.0% and less than 9.0% at screening
- Subject has a (FPG) of less than 10.0 mmol/l
- Subject is treatment naïve to glucose-lowering medication or uses metformin that will be washed out at least 3 weeks prior to the first dosing at Day 1
- Subject's serum creatinine is within the normal range
Inclusion Part B: T2DM subjects
- Subject has a body mass index (BMI) of more than or equal to 20.0 and less than 35.0 kg/m2 at screening.
- Subject has been diagnosed with T2DM for at least 6 months
- Subject has HbA1c level of equal to or more than 6.0% and less than 10% at screening
- Subject has a FPG of less than 10.0 mmol/l
- Subject is drug naïve or on a stable glucose lowering therapy (metformin, TZD, DPP-4 inhibitor or SUD therapy
Exclusion Criteria:
Exclusion Part A: Healthy subjects
- Any of the liver function tests above the upper limit of normal
- A QTc interval of >430 ms (males) and >450 ms (females), a history of unexplained syncope, cardiac arrest, unexplained significant cardiac arrhythmias or torsades de pointes, structural heart disease, or a family history of Long QT Syndrome (LQTS)
- Abnormal pulse and/or blood pressure measurements at screening as follows: Pulse <40 or >90 bpm; mean systolic blood pressure >140 mmHg; mean diastolic blood pressure >90 mmHg
- eGFR (based on Modification of Diet in Renal Disease (MDRD) method) less than 60 ml/min/1.73m2 on Day -2
Exclusion Part A & Part B: T2DM subjects
- Subject has type 1 diabetes mellitus
- A QTc interval of >450 ms (males) and >470 ms (females), a history of unexplained syncope, cardiac arrest, unexplained significant cardiac arrhythmias or torsades de pointes, structural heart disease, or a family history of Long QT Syndrome (LQTS)
- Subject is on an insulin therapy or has received insulin within 3 months prior to screening, with the exception of acute use of <7 days prior to screening
- Subject has a urinary microalbumin/creatinine ratio above or equal to 300 mg/g at screening
- Subject has an ALT and/or AST higher than 3 times the upper limit of normal or has a total bilirubin more than 2 times the upper limit of normal at screening
- Subject has a symptomatic urinary tract infection or symptomatic genito-urinary infection at screening
- Subject has persistent, uncontrolled severe hypertension as indicated by a mean systolic blood pressure > 160 mmHg or a mean diastolic blood pressure of > 100 mmHg
- Subject has significant cardiovascular disease
- eGFR (based on MDRD method) less than 60 ml/min/1.73m2 on Day -2
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Basic Science
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Part A
Ipragliflozin (low dose) & Placebo
|
Oral
Oral
Other Names:
|
Experimental: Part B
Ipragliflozin (high dose)
|
Oral
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Part A: Assessment of glucose homeostasis in fasted condition and after an oral glucose load, following multiple doses of ipragliflozin in healthy subjects and subjects with T2DM
Time Frame: 4 days
|
4 days
|
Part A: Assessment of peripheral glucose utilization after an oral glucose load, following multiple doses of ipragliflozin
Time Frame: 4 days
|
4 days
|
Part A: Assessment of splanchnic uptake after an oral glucose load, following multiple doses of ipragliflozin
Time Frame: 4 days
|
4 days
|
Part A: Assessment of mean glucose levels in fasted condition and after an oral glucose load, following multiple doses of ipragliflozin
Time Frame: 4 days
|
4 days
|
Part B: Assessment of the relationship between the exposure to ipragliflozin in plasma, urinary glucose excretion and plasma glucose levels in subjects with T2DM
Time Frame: 6 days (PK), 12 days (urine) and 8 days (PD)
|
6 days (PK), 12 days (urine) and 8 days (PD)
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Part A: Assessment of steady state urinary sodium excretion and urinary glucose excretion following multiple doses of ipragliflozin
Time Frame: 4 days (sodium) and 14 days (glucose) days
|
4 days (sodium) and 14 days (glucose) days
|
Part A: Assessment of energy production and utilization of energy sources following multiple doses of ipragliflozin
Time Frame: 4 days
|
4 days
|
Part A: Safety and tolerability following multiple doses of ipragliflozin assessed by recording adverse events, laboratory assessments, vital signs, electrocardiograms (ECGs) and signs and symptoms of hypoglycemia
Time Frame: Up to 21 days
|
Up to 21 days
|
Part B: Safety and tolerability following multiple doses of ipragliflozin assessed by recording adverse events, laboratory assessments, vital signs, electrocardiograms (ECGs) and signs and symptoms of hypoglycemia
Time Frame: Up to 21 days
|
Up to 21 days
|
Collaborators and Investigators
Sponsor
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 1941-CL-0050
- 2010-024070-19 (EudraCT Number)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Type 2 Diabetes Mellitus
-
SanofiCompletedType 1 Diabetes Mellitus-Type 2 Diabetes MellitusHungary, Russian Federation, Germany, Poland, Japan, United States, Finland
-
Mannkind CorporationTerminatedType 2 Diabetes Mellitus | Type 1 Diabetes MellitusUnited States
-
Griffin HospitalCalifornia Walnut CommissionCompletedDIABETES MELLITUS TYPE 2United States
-
RWTH Aachen UniversityBoehringer IngelheimCompletedDiabetes Mellitus Type 2 (T2DM)Germany
-
Scripps Whittier Diabetes InstituteSan Diego State UniversityCompletedType 2 Diabetes Mellitus (T2DM)United States
-
University Hospital Inselspital, BerneCompletedType 2 Diabetes MellitusSwitzerland
-
India Diabetes Research Foundation & Dr. A. Ramachandran...CompletedTYpe 2 Diabetes MellitusIndia
-
Daewoong Pharmaceutical Co. LTD.Not yet recruitingT2DM (Type 2 Diabetes Mellitus)
-
Zhongda HospitalRecruitingType 2 Diabetes Mellitus (T2DM)China
-
Shanghai Golden Leaf MedTec Co. LtdRecruitingType 2 Diabetes Mellitus (T2DM)China
Clinical Trials on Placebo
-
SamA Pharmaceutical Co., LtdUnknownAcute Bronchitis | Acute Upper Respiratory Tract InfectionKorea, Republic of
-
National Institute on Drug Abuse (NIDA)CompletedCannabis UseUnited States
-
AstraZenecaParexel; Spandauer Damm 130; 14050; Berlin, GermanyCompletedMale Subjects With Type II Diabetes (T2DM)Germany
-
Heptares Therapeutics LimitedCompletedPharmacokinetics | Safety IssuesUnited Kingdom
-
GlaxoSmithKlineCompletedPulmonary Disease, Chronic ObstructiveUnited Kingdom, Netherlands
-
ItalfarmacoCompletedBecker Muscular DystrophyNetherlands, Italy
-
Shijiazhuang Yiling Pharmaceutical Co. LtdXuanwu Hospital, BeijingCompleted
-
GlaxoSmithKlineCompletedInfections, BacterialUnited States
-
West Penn Allegheny Health SystemCompletedAsthma | Allergic RhinitisUnited States